Publication date: Oct 08, 2024
Intravenous immunoglobulin (IVIG) is an immunomodulatory therapy that has been studied in several neuroimmune conditions, such as Guillain-BarrcE9 Syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and multiple sclerosis. It has also been proposed as a potential treatment option for acute COVID-19 infection and post-acute sequelae of SARS-CoV-2 infection (PASC). IVIG is thought to function by providing the recipient with a pool of antibodies, which can, in turn, modulate immune responses through multiple mechanisms including neutralization of cytokines and autoantibodies, saturation of neonatal fragment crystallizable receptors, inhibition of complement activation, and regulation of T and B cell mediated inflammation. In acute COVID-19, studies have shown that early administration of IVIG and plasmapheresis in severe cases can reduce the need for mechanical ventilation, shorten ICU and hospital stays, and lower mortality. Similarly, in PASC, while research is still in early stages, IVIG has been shown to alleviate persistent symptoms in small patient cohorts. Furthermore, IVIG has shown benefits in another condition which has symptomatic overlap with PASC, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), though studies have yielded mixed results. It is important to note that IVIG can be associated with several potential adverse effects, such as anaphylaxis, headaches, thrombosis, liver enzyme elevations and renal complications. In addition, the high cost of IVIG can be a deterrent for payers and patients. This review provides a comprehensive update on the use of IVIG in multiple neuroimmune conditions, ME/CFS, acute COVID-19, and PASC, as well as covers its history, production, pricing, and mechanisms of action. We also identify key areas of future research, including the need to optimize the use of Ig product dosing, timing, and patient selection across conditions, particularly in the context of COVID-19 and PASC.
| Concepts | Keywords |
|---|---|
| Future | Autoimmune |
| Immunoglobulin | COVID-19 |
| Liver | Intravenous immunoglobulin |
| Plasmapheresis | Long covid |
| Pool | Neuroimmune |
| PASC |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Immune Globulin Human |
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| disease | MESH | post-acute sequelae of COVID-19 |
| disease | MESH | Syndrome |
| disease | MESH | polyneuropathy |
| disease | MESH | multiple sclerosis |
| disease | IDO | cell |
| disease | MESH | inflammation |
| disease | MESH | myalgic encephalomyelitis |
| disease | MESH | anaphylaxis |
| disease | MESH | thrombosis |
| disease | MESH | complications |
| disease | IDO | history |
| disease | IDO | production |